APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST
An open, multicenter, dose-exploring Phase I trial include Part A and Part B to evaluate the safety, tolerability and efficacy of APG-2449.
Platinum-resistant Recurrent Ovarian Cancer|Advanced Solid Tumor
DRUG: APG -2449|DRUG: PLD
Treatment-related adverse events per NCI-CTCAE version 5.0., The number and frequency of adverse events of test drug will be assessed according to CTCAE v5.0., Up to 1 year|Dose Limiting Toxicity(DLT)., DLT will be defined based on the rate of drug-related grade 3 to 5 adverse events experienced within the first 4 weeks of study treatment. These will be assessed per NCI-CTCAE version 5.0., Up to 28 days
Part A: To evaluate the safety of APG-2449 monotherapy in patients with advanced solid tumors.

Part B: To evaluate the safety, tolerability, and efficacy of APG-2449 combined with PLD in the treatment of ovarian cancer.